Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

A Systematic Review on Drug Safety for Molsidomine, Nicorandil and Trimetazidine

Molsidomine, Nicorandil, Trimetazidine의 안전성 관련 체계적 고찰

  • Received : 2016.04.19
  • Accepted : 2016.05.20
  • Published : 2016.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Ischemic heart disease is the most common type of heart disease and an important cause of death in Korea. Among marketed anti-anginal medications, molsidomine, nicorandil, and trimetazidine are approved in Korea with unique mechanism of actions. As these drugs are not approved by the US Food and Drug Administration, the access to the up-to-dated and comprehensive safety-related information has been less than optimal from drug information resources used by Korean pharmacists. Methods: A systematic review was conducted using Embase and Korean manuscripts to compile safety updates for these medications. Out of 418 articles from keyword searches, 52 studies were reviewed in full to compare adverse effects (AEs) with the approved package inserts (PI). Results: Molsidomine related adverse effects were mostly mild or moderate, but anxiety, palpitation, epigastric pain, and sexual potency reduction were additional AEs found from the review not listed in PI. Although PI has included ulceration in oral cavity and gastrointestinal tracts including anus by nicorandil, the Korea FDA recently recommended adding corneal, genital, and skin ulcers to the approved PI. Trimetazidine induced Parkinsonism, worsening of the symptoms for patients diagnosed with Parkinson's disease, gastrointestinal burning, and muscle cramps were additionally identified AEs not listed in PI for trimetazidine. Conclusion: Continuous evaluations of the safety profile of these agents are needed to balance the risks and benefits to provide evidence-based safety counseling to the patients. In addition, more focused efforts on spontaneous reporting are warranted by healthcare professionals to safeguard patients against AEs.

Keywords

References

  1. The average life expectancy (0 years life expectancy) and healthy life. Available from http://www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=2758. Accessed March 25, 2016.
  2. Mortality trends by cause of death. Available from http://www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=1012. Accessed March 25, 2016.
  3. Overview of Korean healthcare system based on the Korea Healthcare Panel (2008-2012). Available from https://www.khp.re.kr:444/ver_2/04_study/study01.jsp. Accessed March 25, 2016.
  4. Vital Statistics in 2014 on Cause of Death. Available from http://kostat.go.kr/portal/korea/kor_nw/2/6/2/index.board?bmode=read&aSeq=348539. Accessed April 14, 2016.
  5. Reden J. Molsidomine. Blood Vessels 1990;27(2-5):282-94.
  6. Markham A, Plosker GL, Goa KL. Nicorandil: An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs 2000;60(4):955-74. https://doi.org/10.2165/00003495-200060040-00007
  7. Horinaka S. Use of nicorandil in cardiovascular disease and its optimization. Drugs 2011;71(9):1105-19. https://doi.org/10.2165/11592300-000000000-00000
  8. Cross HR. Trimetazidine for stable angina pectoris. Expert Opin on Pharmacother 2001;2(5):857-75. https://doi.org/10.1517/14656566.2.5.857
  9. Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: Some insights on its role in heart failure and peripheral artery disease. Drugs 2014;74(9):971-80. https://doi.org/10.1007/s40265-014-0233-5
  10. Roland E. Safety profile of an anti-anginal agent with potassium channel opening activity: An overview. Eur Heart J 1993;14(suppl. B):48-52.
  11. Sasaki J, Saeki Y, Kawasaki K, et al. A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease. Cardiovac Drugs Ther 1992;6(5):471-4. https://doi.org/10.1007/BF00055603
  12. Wagner G. Selected issues from an overview on nicorandil: Tolerance, duration of action, and long-term efficacy. J Cardiovasc Pharmacol 1992;20(suppl. 3):S86-92. https://doi.org/10.1097/00005344-199206203-00015
  13. Krumenacker M, Roland E. Clinical profile of nicorandil: An overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 1992;20(suppl. 3):S93-102.
  14. Dunn N, Freemantle S, Pearce G, et al. Safety profile of nicorandil - Prescription-event monitoring (PEM) study. Pharmacoepidemiol Drug Saf 1999;8(3):197-205. https://doi.org/10.1002/(SICI)1099-1557(199905/06)8:3<197::AID-PDS422>3.0.CO;2-T
  15. Terai H, Yamanishi H, Shimahara M. Nicorandil-induced tongue ulceration with or without fungal infection. Odontology 2012;100(1):100-3. https://doi.org/10.1007/s10266-011-0015-4
  16. Scully C, Azul AM, Crighton A, et al. Nicorandil can induce severe oral ulceration. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;91(2):189-93. https://doi.org/10.1067/moe.2001.110306
  17. Egred M. Nicorandil-associated ulcerations. Eur J Gastroenterol Hepatol 2007;19(5):395-8. https://doi.org/10.1097/MEG.0b013e328010b184
  18. Salim F, Joshi A, Hopkins C. Ulceration of the nasal dorsum: a rare cause? J Laryngol Otology 2014;128(3):289-91. https://doi.org/10.1017/S0022215113003629
  19. Gayet JL, Paganelli F, Cohen-Solal A. Update on the medical treatment of stable angina. Arch Cardiovas Dis 2011;104(10):536-44. https://doi.org/10.1016/j.acvd.2011.08.001
  20. Fraunfelder FW, Fraunfelder FT. Conjunctival and corneal ulceration associated with nicorandil. Cutan Ocul Toxicol 2014;33(2):120-1. https://doi.org/10.3109/15569527.2013.811248
  21. Trechot F, Batta B, Petitpain N, et al. A case of nicorandil-induced unilateral corneal ulceration. Int Wound J 2014;11(3):238-9. https://doi.org/10.1111/iwj.12081
  22. Campolmi N, Guy C, Cinotti E, et al. Corneal perforation: Another side effect of nicorandil. Cutan Ocul Toxicol 2014;33(2):96-8. https://doi.org/10.3109/15569527.2013.812105
  23. Trechot P, Petitpain N, Guy C, et al. Nicorandil: From ulcer to fistula into adjacent organs. Int Wound J 2013;10(2):210-3. https://doi.org/10.1111/j.1742-481X.2012.00966.x
  24. Shapey IM, Agbamu D, Newall N, et al. Nicorandil-associated ulceration of the gastrointestinal tract: side effects requiring surgical intervention. Int J of Colorectal Dis 2015;30(8):1143-5. https://doi.org/10.1007/s00384-014-2112-7
  25. McClellan KJ, Plosker GL. Trimetazidine: A review of its use in stable angina pectoris and other coronary conditions. Drugs 1999;58(1):143-57. https://doi.org/10.2165/00003495-199958010-00016
  26. Marti Masso JF, Marti I, Carrera N, et al. Trimetazidine induces parkinsonism, gait disorders and tremor. Therapie 2005;60(4):419-22. https://doi.org/10.2515/therapie:2005061
  27. Marti Masso JF. Trimetazidine-induced parkinsonism. Neurologia 2004;19(7):392-5.
  28. Masmoudi K, Masson H, Gras V, et al. Extrapyramidal adverse drug reactions associated with trimetazidine: A series of 21 cases. Fundam Clin Pharmacol 2012;26(2):198-203. https://doi.org/10.1111/j.1472-8206.2011.01008.x
  29. Messin R, Dubois C, Famaey JP. Comparative effects of once-daily molsidomine in coronary patients from two distinct European ethnicities. Adv Ther 2008;25(11):1200-14. https://doi.org/10.1007/s12325-008-0117-8
  30. Messin R, Carreer-Bruhwyler F, Dubois C, et al. Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: Double-blind and open-label studies. Adv Ther 2006;23(1):107-30. https://doi.org/10.1007/BF02850352
  31. Beaufils P, Kolsky H, Haiat R, et al. The influence of molsidomine on infarct size: An acute post-infarction pilot study with 303 patients. Cardiovasc Drugs Ther 1988;2(1):127-32. https://doi.org/10.1007/BF00054263
  32. Balakumaran K, Hugenholtz PG, Tijssen JGP, et al. Molsidomine, an effective long-acting anti-anginal drug. Eur Heart J 1983;4(9):655-61. https://doi.org/10.1093/oxfordjournals.eurheartj.a061538
  33. Nishimura M, Tokoro T, Nishida M, et al. Oral Nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: A randomized trial. Am J Kidney Dis 2009;54(2):307-17. https://doi.org/10.1053/j.ajkd.2009.03.025
  34. Blanc P, Aouifi A, Bouvier H, et al. Safety of oral nicorandil before coronary artery bypass graft surgery. Br J Anaesth 2001;87(6):848-54. https://doi.org/10.1093/bja/87.6.848
  35. Wolf DL, Hearron AE, Metzler CM, et al. The pharmacokinetics and haemodynamic effects of continuous nicorandil infusion in healthy volunteers. Eur J Clin Pharmacol 1993;45(5):437-43. https://doi.org/10.1007/BF00315515
  36. Ulvenstam G, Diderholm E, Frithz G, et al. Antianginal and antiischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992;20(suppl. 3):S67-73. https://doi.org/10.1097/00005344-199206203-00012
  37. Doring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: Results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992;20(suppl. 3):S74-81.
  38. Raftery EB, Lahiri A, Hughes LO, et al. A double-blind comparison of a beta-blocker and a potassium channel opener in exercise induced angina. Eur Heart J 1993;14(suppl. B):35-9. https://doi.org/10.1093/eurheartj/14.suppl_B.35
  39. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91(2):161-5. https://doi.org/10.1136/hrt.2003.031310
  40. Shlyakhto EV, Almazov VVA, Nifontov EM, et al. Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris. Am J Cardiovasc Drugs 2002;2(2):119-24. https://doi.org/10.2165/00129784-200202020-00005
  41. Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study. Cardiovasc Drugs Ther 1990;4(suppl. 4):853-9. https://doi.org/10.1007/BF00051292
  42. Ruzyllo W, Szwed H, Sadowski Z, et al. Efficacy of trimetazidine in patients with recurrent angina: A subgroup analysis of the TRIMPOL II study. Curr Med Res Opin 2004;20(9):1447-54. https://doi.org/10.1185/030079904X2637
  43. Bertel O, Noll G. Additional molsidomine in refractory unstable angina pectoris. Cardiovasc Drugs Ther 1988;2(1):107-11. https://doi.org/10.1007/BF00054260
  44. Makolkin VI, Osadchiy KK. Trimetazidine modified release in the treatment of stable angina: TRIUMPH Study. Clin Drug Investig 2004;24(12):731-8. https://doi.org/10.2165/00044011-200424120-00004
  45. Palaniappan M, Selvarajan S, George M, et al. Pattern of adverse drug reactions reported with cardiovascular drugs in a tertiary care teaching hospital. J Clin Diagn Res 2015;9(11):FC01-4.
  46. Toquero L, Briggs CD, Bassuini MM, et al. Anal ulceration associated with nicorandil: Case series and review of the literature. Colorectal Disease 2006;8(8):717-20. https://doi.org/10.1111/j.1463-1318.2006.00972.x
  47. Kapoor S. Nicorandil and its associated gastrointestinal side effects. Pacing Clin Electrophysiol 2013;36(5):662. https://doi.org/10.1111/pace.12105
  48. Baker RP, Al-Kubati W, Atuf M, et al. Nicorandil-induced severe perianal ulceration. Tech Coloproctol 2007;11(4):343-5. https://doi.org/10.1007/s10151-007-0378-2
  49. Yap T, Philippou P, Perry M, et al. Nicorandil-induced penile ulcerations: A case series. BJU Int 2011;107(2):268-71. https://doi.org/10.1111/j.1464-410X.2010.09463.x
  50. McDaid J, Reichl C, Hamzah I, et al. Diverticular fistulation is associated with nicorandil usage. Ann R Coll Surg Engl 2010;92(6):463-5. https://doi.org/10.1308/rcsann.2010.92.6.463
  51. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990;4(4):1075-88. https://doi.org/10.1007/BF01856503
  52. Balakumar P, Kavitha M, Nanditha S. Cardiovascular drugs-induced oral toxicities: A murky area to be revisited and illuminated. Pharmacol Res 2015;102:81-9. https://doi.org/10.1016/j.phrs.2015.09.007
  53. Onay-Besikci A, Özkan SA. Trimetazidine revisited: A comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine. Cardiovas Ther 2008;26(2):147-65. https://doi.org/10.1111/j.1527-3466.2008.00043.x
  54. The Korean-English Medical Terminology, 5th Edition, Korean Medical Association. Available from http://term.kma.org/. Accessed April 14, 2016.
  55. Lehmann G, Reiniger G, Beyerle A, et al. Clinical comparison of antiischemic efficacy of isosorbide dinitrate and molsidomine. J Cardiovasc Pharmacol 1998;31(1):25-30. https://doi.org/10.1097/00005344-199801000-00004
  56. Lehmann G, Reiniger G, Beyerle A, et al. Haemodynamic evaluation of two regimens of molsidomine in patients with chronic congestive heart failure. Eur J Clin Pharmacol 1995;48(2):109-14. https://doi.org/10.1007/BF00192734
  57. Falase BA, Bajaj BS, Wall TJ, et al. Nicorandil-induced peripheral vasodilatation during cardiopulmonary bypass. Ann Thorac Surg 1999;67(4):1158-9. https://doi.org/10.1016/S0003-4975(99)00132-0
  58. Bricaud H, Brottier L, Barat JL, et al. Cardioprotective effect of trimetazidine in severe ischemic cardiomyopathy. Cardiovasc Drugs Ther 1990;4 Suppl 4:861-5. https://doi.org/10.1007/BF00051293
  59. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990;11(3):207-12. https://doi.org/10.1093/oxfordjournals.eurheartj.a059685